Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2707

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 7
Chunk 2707
---
 to deliver any shares of Common Stock issuable upon exercise.

If at the time of exercise
of the Series C Common Warrants, there is no effective registration statement registering the shares of the Common Stock underlying the
Series C Common Warrants, such warrants may be exercised on a cashless basis pursuant to their terms.

If we issue options, convertible
securities, warrants, shares, or similar securities to holders of Common Stock, each holder of Series C Common Warrants has the right
to acquire the same as if the holder had exercised its Series C Common Warrants. The holders of Series C Common Warrants are entitled
to receive any dividends paid or distributions made to our holders of Common Stock on an “as if converted” basis.

F-24

The Series C Common Warrants
prohibit us from entering into specified fundamental transactions unless the successor entity assumes all of our obligations under the
Series C Common Warrants under a written agreement before the transaction is completed. Upon specified corporate events, a holder of Series
C Common Warrants will thereafter have the right to receive upon an exercise such shares, securities, cash, assets or any other property
whatsoever which the holder would have been entitled to receive upon the happening of the applicable corporate event had the Series C
Common Warrants been exercised immediately prior to the applicable corporate event. When there is a transaction involving specified changes
of control, a holder of Series C Common Warrants can request the Company to exchange the then unexercised portion of their Series C Common
Warrants for consideration equal to the Black-Scholes value thereof, which shall be settled, at the option of the Company in either (i)
the form of rights convertible into the consideration receivable by holders of the underlying shares of common stock, based upon the value
of the shares of the successor entity over a specified period or (ii) cash in an amount equal to the Black-Scholes value.

The Company’s Series
C Common Warrants are exercisable into Common Stock and are recorded as equity.

December 2024 Common Warrants (Successor)

On December 23, 2024, the
Company issued warrants to purchase an aggregate of 84,061 shares of Common Stock to certain investors affiliated with each other to induce
investors to exercise their Series A Preferred Warrants for cash (the “December 2024 Common Warrants”). The December 2024
Common Warrants are initially exercisable for cash at an initial exercise price equal to $5.61 (